Meplazumab Completed Phase 3 Trials for Coronavirus Disease 2019 (COVID‑19) / Post-Covid 19 Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT05813587 | To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19 |